BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company

SAN FRANCISCO — Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit.

BioMarin Pharmaceutical has done all …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Expert analysis: the latest in HIV research and clinical trials – Pharmaceutical Technology

Share this article An image of the HIV virus. Credit: Shutterstock Novotech’s latest report explores the latest developments in cutting-edge research for HIV, including long-acting

January 3, 2024

What’s Behind the Decrease in Breast Cancer Deaths?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

January 21, 2024

Fresenius raises outlook for fiscal year 2024 – Biotech Investments

Fresenius SE & Co. KGaA / Key word(s): Change in Forecast Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 07-May-2024 /

May 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.